Boromycin
| Code | Size | Price |
|---|
| TAR-T36659-5mg | 5mg | £1,099.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Boromycin is a boron-containing macrolide antibiotic that has been found in Streptomyces. Boromycin inhibits growth of B. subtilis (MIC = 0.05 μg/ml) and induces efflux of potassium ions from B. subtilis without affecting Na+/K+-ATPase activity. It decreases the synthesis of protein, RNA, and DNA in B. subtilis when used at a concentration of 0.05 μg/ml. It inhibits the growth of B. halodurans (MIC = 10 ng/ml) and inhibits the futalosine pathway of menaquinone synthesis in B. halodurans. Boromycin (3.4 nM) reverses bleomycin-induced cell cycle arrest at the G2 phase in Jurkat cells. It inhibits replication of the HIV-1 strains LAV-1 and RF and the HIV-2 strain LAV-2 in MT-4 cells (IC50s = 0.008, 0.11, and 0.007 μM, respectively). It also inhibits replication of a clinical isolate of HIV-1, strain KK-1, in MT-4 cells and peripheral blood mononuclear cells (PBMCs; IC50s = 0.14 and <0.1 μM, respectively).
CAS:
34524-20-4
Formula:
C45H73BNO15?H
Molecular Weight:
879.9
Purity:
0.98
SMILES:
C[C@H](CC[C@@H](C(C)([C@H](CC/C=C/C[C@@H]([C@@H](C)OC([C@H](N)C(C)C)=O)O1)O)C)O2)[C@]32[O-][B+3]4([O-][C@]5(O[C@H](C6(C)C)CC[C@H]5C)[C@H](C1=O)[O-]4)[O-][C@H]3C(O[C@H]7C[C@@H](CCC[C@H]6O)O[C@@H]7C)=O.[H+]